Ranitidine

Generic Name: Ranitidine

Brand Names: Good Sense Acid Reducer, Wal-zan, Zantac

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₂N_₄O_₃S

CAS Number: 66357-35-5

Unique Ingredient Identifier: 884KT10YB7

Background: Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available...

Indication: This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastr...

Associated Conditions: Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Associated Therapies: -

Clinical Trials

Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering

Phase 2

Conditions: Post Anaesthetic Shivering

Interventions: Drug: Nefopam
Drug: Tramadol
Drug: Metoclopramide
Drug: Ranitidine
Drug: Pethidine
Drug: Ephedrine
Drug: oxytocin

First Posted Date: 2015-05-12

Last Posted Date: 2018-07-17

Lead Sponsor: Lagos State Health Service Commission

Target Recruit Count: 130

Registration Number: NCT02441673

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: CABAZITAXEL XRP6258
Drug: PEG-G-CSF
Drug: Prednisolone
Drug: Dexchlorpheniramine or Diphenhydramine
Drug: Ranitidine
Drug: Metoclopramide, Granisetron, or Ondansetron
Drug: Dexamethasone

First Posted Date: 2015-05-12

Last Posted Date: 2017-01-24

Lead Sponsor: Sanofi

Target Recruit Count: 21

Registration Number: NCT02441894

Locations: 🇯🇵
Investigational Site Number 392008, Kita-gun, Japan
🇯🇵
Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan
🇯🇵
Investigational Site Number 392004, Chuo-ku, Chiba, Japan

and more 5 locations

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: cetirizine
Drug: ranitidine
Drug: methylprednisolone
Drug: aciclovir
Drug: esomeprazole
Drug: ibuprofen
Drug: paracetamol

First Posted Date: 2014-07-31

Last Posted Date: 2016-06-09

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 58

Registration Number: NCT02205489

Locations: 🇧🇪
Investigational Site Number 056001, Brussels, Belgium
🇳🇱
Investigational Site Number 528001, Breda, Netherlands
🇳🇱
Investigational Site Number 528002, Rotterdam, Netherlands

and more 17 locations

A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain

Phase 4

Completed

Conditions: Dyspepsia

Interventions: Drug: esomeprazole
Drug: hydrotalcid
Drug: Ranitidine

First Posted Date: 2014-07-22

Last Posted Date: 2014-07-22

Lead Sponsor: Pamukkale University

Target Recruit Count: 286

Registration Number: NCT02197143

Locations: 🇹🇷
Pamukkale Universty, Denizli, Turkey

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS
Drug: Ranitidine

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02170792

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

Phase 4

Withdrawn

Conditions: Eustachian Tube Dysfunction
Laryngopharyngeal Reflux

Interventions: Drug: Omeprazole
Drug: Ranitidine
Drug: Pantoprazole
Procedure: 24-Hour Diagnostic pH-Probe Test
Procedure: Laryngoscopy

First Posted Date: 2014-04-25

Last Posted Date: 2016-09-26

Lead Sponsor: Loma Linda University

Registration Number: NCT02123498

Locations: 🇺🇸
1895 Orange Tree Lane, Suite 102, Redlands, California, United States
🇺🇸
11234 Anderson Street, Loma Linda, California, United States